PharmCAT.NET

Biostatistics, pharmacokinetics and clinical trials.

  • Home page
  • Blog
  • Contacts
  • Agreement & Confidentiality

IBM SPSS Extension: R Project PowerTOST library

Posted on December 31, 2018December 31, 2018 by frozencat

IBM SPSS Extension PowerTOST R Project library. Syntax command: POWERTOST.

Version: 1.0.0

Functions:

  • power.TOST
  • sampleN.TOST
  • CVfromCI

Дизайны:

  • parallel
  • 2×2
  • 2x2x4

Скачать/Download

GitHUB: https://github.com/PharmCat/SPSSPowerTOST

Categories: Blog, SPSS

Post navigation

Next Post:

Recent Posts

  • IBM SPSS + R Project: Confidence intervals for proportions, independent groups
  • IBM SPSS Extension: R Project PowerTOST library

Галерея

IMG-20170802-WA0016
20180811 235329
DJI 0030
20180815 133138
20180202 170523
20170729 211926 (1)
  • Human medicines European public assessment report (EPAR): Actelsar HCT, telmisartan,hydrochlorothiazide, Date of authorisation: 13/03/2013, Revision: 19, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-05-13
  • Human medicines European public assessment report (EPAR): Enbrel, etanercept, Date of authorisation: 02/02/2000, Revision: 75, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-05-13
  • Human medicines European public assessment report (EPAR): Dyrupeg, pegfilgrastim, Date of authorisation: 28/03/2025, Revision: 2, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-05-13
  • Compounding Quality Center of Excellence | Engage with the Compounding Quality Center of Excellence
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-05-13 By FDA
  • Human medicines European public assessment report (EPAR): Datroway, datopotamab deruxtecan, Date of authorisation: 04/04/2025, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-05-13
  • IXCHIQ
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-05-13 By FDA
  • Tissue Guidances
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-05-12 By FDA
  • Allergenics
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-05-12 By FDA
  • eSubmitter Application History
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-05-12 By FDA
  • Development & Approval Process (CBER)
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-05-12 By FDA
  • Untitled Letters
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-05-12 By FDA
  • FDA and CDC Recommend Pause in Use of Ixchiq (Chikungunya Vaccine, Live) in Individuals 60 Years of Age and Older While Postmarketing Safety Reports are Investigated: FDA Safety Communication
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-05-12 By FDA
  • Human medicines European public assessment report (EPAR): Xyrem, sodium oxybate, Date of authorisation: 13/10/2005, Revision: 37, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-05-12
  • GDUFA Type II API DMF Payment Receipts Report
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-05-12 By FDA
  • Human medicines European public assessment report (EPAR): Dimethyl fumarate Mylan, dimethyl fumarate, Date of authorisation: 22/04/2024, Revision: 2, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-05-12
Older posts
Theme: Scaffold by Danny Cooper.